Date: Thursday, December 3, 2026
Time: 11:00am - 12:00pm ET
Products: CODEX Clinical Outcomes Databases
Summary
What can existing clinical trial evidence tell you about the potential of your next drug candidate, and how can you use that evidence to make better development decisions?
Join Certara experts Matt Zierhut and Roman Casciano to explore how publicly available clinical trial evidence, curated through CODEX Analytics and analyzed using model-based meta-analysis (MBMA), can provide quantitative insights to support drug development decisions.
See how CODEX helps teams identify relevant studies, explore treatment outcomes, compare therapies, and uncover evidence gaps. Learn how MBMA builds on that evidence to characterize treatment effects and dose-response relationships, benchmark treatment performance, and evaluate development scenarios.
Through real-world examples, Matt and Roman will show how these approaches can inform dose selection, clinical trial design, treatment differentiation, development strategy, and regulatory interactions. They will also discuss how CODEX, customized databases, and quantitative analyses can complement internal databases, AI-enabled curation, and data science capabilities.
Register now
Matt Zierhut, PhD MBA
Vice President, MBMA Capability Lead, Certara Drug Development SolutionsMatt advances the integration of published clinical outcomes data into development decisions and commercial and regulatory strategy via model-based meta-analysis (MBMA). Matt works closely with clinical development teams to ensure MBMA is leveraged for optimal impact when making the most critical decisions.
Roman Casciano, MEng
SVP, Evidence & AccessAs an applied health economist and market access strategist, Roman has personally led hundreds of engagements in the global market access, HEOR and real-world evidence context related to product value demonstration and has deep experience in both formal and informal exchanges with payers and HTA bodies.
Register now
